23andMe (NASDAQ:ME) Earns Sell (E+) Rating from Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

23andMe Trading Up 1.7 %

Shares of 23andMe stock opened at $1.79 on Friday. The company’s 50-day moving average price is $2.55 and its two-hundred day moving average price is $3.93. 23andMe has a 52 week low of $1.34 and a 52 week high of $12.76. The stock has a market cap of $48.02 million, a PE ratio of -0.12 and a beta of 1.19.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

Institutional Trading of 23andMe

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after buying an additional 28,252 shares during the period. FMR LLC raised its holdings in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock worth $345,000 after buying an additional 192,099 shares during the period. Shay Capital LLC raised its holdings in 23andMe by 71.7% during the 4th quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock worth $2,283,000 after buying an additional 293,358 shares during the period. Virtu Financial LLC acquired a new stake in 23andMe during the 4th quarter worth about $49,000. Finally, MassMutual Private Wealth & Trust FSB purchased a new position in 23andMe during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.